134
Participants
Start Date
February 28, 2013
Primary Completion Date
September 30, 2016
Study Completion Date
September 30, 2016
Experimental: Valacyclovir treatment
Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
Placebo comparator
Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
Dr. Ram Manohar Lohia Hospital, Delhi
Dr. Ram Manohar Lohia Hospital
OTHER_GOV
Stanley Medical Research Institute
OTHER
University of Pittsburgh
OTHER